Juvenile Interstitial Lung Disease (chILD)

Overview

Juvenile interstitial lung disease (chILD) is a heterogeneous group of rare, chronic lung disorders that affect children from birth to 18 years of age. The disease is characterised by inflammation and/or fibrosis (scarring) of the lung interstitium – the tissue that surrounds the air‑filled alveoli and blood vessels. This disrupts gas exchange, leading to progressive shortness of breath and reduced oxygenation.

Who it affects: While chILD can be diagnosed at any pediatric age, the highest incidence occurs in infants and toddlers (< 2 years). Some genetic forms present at birth, whereas others (e.g., hypersensitivity pneumonitis) appear later in childhood.

Prevalence: Exact numbers are difficult to ascertain because of under‑recognition, but epidemiologic surveys estimate an incidence of 0.13–0.5 cases per 100,000 children per year in North America and Europe.^{[1] CDC; [2] European Respiratory Society} The condition is considered “orphan” (rare) by the U.S. Orphan Drug Act.

Symptoms

Symptoms can be subtle at first and often overlap with more common pediatric respiratory illnesses. A thorough list includes:

• Persistent cough – usually dry, may be worse at night.
• Shortness of breath (dyspnea) – especially during activity or feeding in infants.
• Rapid breathing (tachypnea) – noticeable at rest in severe cases.
• Chest retractions – inward movement of the chest wall during inspiration.
• Wheezing or crackles – heard with a stethoscope; “fine crackles” are classic.
• Failure to thrive – poor weight gain or weight loss despite adequate nutrition.
• Exercise intolerance – fatigue or inability to keep up with peers.
• Recurrent respiratory infections – pneumonia or bronchitis that respond poorly to antibiotics.
• Clubbing of the fingers – thickened fingertips, more common in chronic disease.
• Nighttime hypoxemia – low oxygen levels while sleeping, may cause restless sleep.
• Developmental delays – secondary to chronic hypoxia or prolonged hospitalisation.

Causes and Risk Factors

chILD is not a single disease; it comprises > 200 distinct entities. The main categories are:

Genetic Disorders

• Surfactant protein deficiencies (SFTPB, SFTPC, ABCA3)
• Telomere‑related diseases (TERT, RTEL1)
• Neuro‑endocrine cell hyperplasia of infancy (NEHI)
• Alveolar capillary dysplasia with mis‑alignment of pulmonary veins (ACD/MPV)

Immune‑Mediated Conditions

• Autoimmune diseases (e.g., juvenile rheumatoid arthritis‑associated interstitial lung disease)
• Hypersensitivity pneumonitis from environmental antigens

Infectious Triggers

• Severe viral infections (e.g., RSV, CMV) that leave a chronic inflammatory scar

Other Causes

• Exposure to inhaled toxins (e.g., second‑hand smoke, occupational dusts in older children)
• Medication‑induced lung injury (e.g., chemotherapy, amiodarone)

Risk factors include a family history of interstitial lung disease, consanguineous parents (increasing recessive genetic forms), prematurity, and chronic exposure to indoor pollutants.

Diagnosis

Because symptoms are non‑specific, a systematic approach is essential.

Initial Evaluation

1. Detailed history & physical exam – focusing on growth patterns, exposure history, and extra‑pulmonary signs (e.g., skin rash, joint swelling).
2. Baseline laboratory tests – complete blood count, inflammatory markers (CRP, ESR), auto‑antibody panels, and, when a genetic cause is suspected, targeted gene panels or whole‑exome sequencing.
3. Chest radiograph – may show diffuse infiltrates, ground‑glass opacities, or cystic changes but lacks specificity.

Advanced Imaging

• High‑resolution computed tomography (HRCT) – the gold‑standard imaging test. Typical findings: reticular pattern, honeycombing, ground‑glass opacities, or mosaic attenuation. HRCT can suggest a specific subtype (e.g., NEHI shows “airway‑centric” ground glass in the right middle lobe and lingula).

Pulmonary Function Tests (PFTs)

• In children > 5 years, spirometry often reveals a restrictive pattern (reduced forced vital capacity) and decreased diffusion capacity (DLCO).

Invasive Procedures

• Bronchoscopy with bronchoalveolar lavage (BAL) – helps to rule out infection and can provide cellular patterns suggestive of certain ILDs.
• Surgical lung biopsy – considered when non‑invasive tests are inconclusive. Histopathology remains the definitive diagnostic tool for many subtypes.

Multidisciplinary discussion (pulmonology, radiology, pathology, genetics, and rheumatology) is strongly recommended to reach a consensus diagnosis.^{[3] European Respiratory Society Guidelines}

Treatment Options

Treatment is tailored to the underlying cause, severity, and age of the child. Goals are to reduce inflammation, slow fibrosis, improve oxygenation, and support growth.

Pharmacologic Therapy

• Corticosteroids (e.g., prednisone, methylprednisolone) – first‑line for inflammatory forms; dosing depends on severity (often 1–2 mg/kg/day with taper).
• Immunomodulators – azathioprine, mycophenolate mofetil, or cyclophosphamide for steroid‑refractory disease.
• Anti‑fibrotic agents – nintedanib and pirfenidone are approved for adult idiopathic pulmonary fibrosis and are being studied in select pediatric cohorts; off‑label use requires specialist oversight.
• Targeted therapies – for surfactant protein deficiencies, lung‑directed gene therapy is experimental; lung‑transplant evaluation may be necessary for end‑stage disease.
• Antibiotics/Antifungals – prophylaxis against opportunistic infections when high‑dose steroids or immunosuppressants are used.

Supportive Measures

• Supplemental oxygen – via nasal cannula or home oxygen concentrator to maintain SpO₂ > 92 % at rest.
• Mechanical ventilation – for acute respiratory failure; non‑invasive positive pressure ventilation (NIPPV) may be used in chronic settings.
• Nutritional support – high‑calorie, high‑protein diets, or gastrostomy feeding to address failure to thrive.
• Pulmonary rehabilitation – age‑appropriate exercise programs to improve endurance.

Procedures

• Lung transplantation – considered for children with progressive, end‑stage disease despite maximal medical therapy. Survival rates improve with early referral and multidisciplinary care.

Lifestyle & Environmental Modifications

• Avoid tobacco smoke, vaping, and indoor pollutants.
• Vaccinations – influenza, pneumococcal, RSV prophylaxis (palivizumab) for high‑risk infants.
• Seasonal infection prevention – hand hygiene, avoiding crowded indoor settings during viral peaks.

Living with Juvenile Interstitial Lung Disease

Managing chILD is a lifelong partnership between families, clinicians, and schools.

Daily Management Tips

1. Medication adherence – use pill organizers, set alarms, and involve school nurses.
2. Oxygen therapy – keep portable oxygen devices charged; teach the child to recognize low‑oxygen symptoms.
3. Nutrition – schedule regular weight checks; consult a pediatric dietitian for calorie‑dense meals.
4. Physical activity – encourage gentle aerobic activities (e.g., swimming, walking) while monitoring fatigue.
5. School accommodations – 504 Plan or Individualized Education Program (IEP) for extra breaks, home‑bound instruction during exacerbations, and safe classroom air quality.
6. Psychosocial support – counseling, support groups, and connection with other families facing chILD can reduce anxiety and improve coping.
7. Regular follow‑up – at least every 3–6 months with a pediatric pulmonologist, plus annual eye exams and bone‑density scans if long‑term steroids are used.

Prevention

Because many forms have a genetic basis, primary prevention is limited. However, secondary prevention (preventing disease progression and exacerbations) includes:

• Ensuring a smoke‑free home and car environment.
• Prompt treatment of respiratory infections; consider antiviral prophylaxis during outbreaks.
• Up‑to‑date vaccinations (influenza, COVID‑19, pneumococcus, pertussis).
• Screening siblings for known genetic mutations when a hereditary form is diagnosed.
• Avoiding exposure to known occupational or environmental dusts (e.g., woodworking, bird droppings) in older children.

Complications

If left untreated or inadequately managed, chILD can lead to serious, sometimes irreversible complications:

• Progressive respiratory failure – requiring long‑term ventilation or transplant.
• Pulmonary hypertension – high blood pressure in lung arteries, worsening right‑heart function.
• Cor pulmonale – right‑ventricular enlargement secondary to chronic hypoxia.
• Growth retardation – due to chronic hypoxia and increased metabolic demand.
• Bone demineralisation – long‑term steroid use can cause osteopenia/osteoporosis.
• Increased susceptibility to infections – from immunosuppressive therapies.
• Psychosocial impact – school absenteeism, anxiety, and reduced quality of life.

When to Seek Emergency Care

---

References

1. Centers for Disease Control and Prevention. “Rare Lung Diseases in Children.” 2022.
2. European Respiratory Society Task Force on Pediatric Interstitial Lung Disease. *Eur Respir J*. 2021;57:2002995.
3. Newton G, et al. Multidisciplinary Approach to Childhood Interstitial Lung Disease. *Lancet Respir Med*. 2020;8(5):511‑525.